Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin; amlodipine - film-coated tablet - 10 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin; amlodipine - film-coated tablet - 10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin; amlodipine - film-coated tablet - 20 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin calcium; amlodipine besilate - film-coated tablet - 20 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin calcium; amlodipine besilate - film-coated tablet - 15 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - rosuvastatin calcium; amlodipine besilate - film-coated tablet - 15 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 10 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination